Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on September 22, 2025
Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction
DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (“Strive”) entered into a definitive agreement to acquire Semler Scientific, Inc. (“Semler Scientific”) in an all-stock transaction. In addition, Strive announced the purchase of …
Aivista Quant Capital Launches Caelus AI and AQC Token Ecosystem, Ushering in a New Era of Intelligent Investing
Denver, CO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Aivista Quant Capital, a financial technology firm focused on next-generation investment solutions, today announced the official launch of its Caelus AI system and the AQC token ecosystem. This milestone marks …
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial sites activated …
24/7 Market News: Kraig Labs Targets Eco Luxury Spider Silk Apparel Market
DENVER, Sept. 22, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today issued a market update highlighting the emerging opportunity in eco luxury spider …
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its …
Biognosys to Launch Metabolomics/Lipidomics Services for Multiomics Drug Discovery and Clinical Research
BOSTON and ZUERICH, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Biognosys, a pioneer in next-generation proteomics services and software, today announced the expansion of its contract research organization (CRO) services to include quantitative …
Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement Disorders
Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in functional and non-motor symptoms in patients with early-stage Parkinson’s disease Solengepras was generally well-tolerated during the 12 …
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that it will host an in-person and virtual KOL event at the …
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
electroCore’s Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards
ROCKAWAY, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its Truvaga™ Plus handheld vagus nerve stimulation (nVNS) device has been named the “ …
Idebenone Accepted by FDA for Priority Review for Leber Hereditary Optic Neuropathy (LHON)
FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 People living with LHON suffer from rapid and severe loss of …
ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study
Study led by CureShank Aims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system MADRID and CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a …
Connect Names Gretel von Son as Chief Operating Officer to Drive Growth in Entrepreneurship and Innovation
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Connect, a premier nonprofit organization in San Diego’s innovation ecosystem, dedicated to supporting entrepreneurs and cultivating thriving life science and technology communities, announced today the …
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has had a positive preliminary clinical …
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being …
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients Second investigator-initiated trial to evaluate efti in earlier stage …
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful …
Voltus Ranked #1 Aggregator in GW Under Management and C&I Programs in Wood Mackenzie’s 2025 VPP Report
SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Voltus, Inc. ("Voltus"), the leading virtual power plant (VPP) operator and distributed energy resource (DER) platform, has once again been named a Leader in Wood Mackenzie’s 2025 North America Virtual …
Advent Technologies Delivers State-of-the-Art Portable Fuel Cell Systems under Contract with the U.S. Department of Defense
LIVERMORE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in fuel cells and hydrogen technologies, has delivered its next generation, state-of-the-art Honey Badger 50™ (“HB50”) …
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026) ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq …